RecruitingNot ApplicableNCT07148830

Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.

Effect of Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma on Local Disease Control and Survival.

Sponsor

Minia University

Enrollment

100 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma

Summary

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis. Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local recurrence, and enhance overall survival compared to standard pancreatoduodenectomy. However, most existing studies are retrospective with heterogeneous patient populations and surgical techniques. This prospective study aims to evaluate the impact of mesopancreatic excision, a surgical technique involving the meticulous removal of retroperitoneal tissue surrounding major peripancreatic vessels, on local disease control and overall survival in patients undergoing pancreaticoduodenectomy for resectable PDAC. The study will also assess R0 resection rates, disease-free survival, recurrence patterns and perioperative outcomes.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a specific surgical technique called mesopancreatic excision in patients having surgery (Whipple procedure) for pancreatic head cancer. Researchers want to see if this more thorough surgical approach improves cancer removal and outcomes. **You may be eligible if...** - You are 18 years or older - You have been confirmed to have pancreatic head adenocarcinoma (a specific type of pancreatic cancer, confirmed by biopsy) - Your cancer is considered surgically removable (resectable) by current medical guidelines - You are scheduled for a Whipple procedure (pancreaticoduodenectomy) - Your general health and organ function are adequate **You may NOT be eligible if...** - Your cancer is borderline resectable or unresectable - Your cancer has spread to distant organs (metastases) - You have had prior chemotherapy or radiation for this cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETotal Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)

* All patients undergo pancreaticoduodenectomy with total mesopancreatic excision (TMpE) and Adjuvant chemotherapy. * Meticulous dissection and en bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels (superior mesenteric artery and portal vein) and the celiac axis, performed during pancreaticoduodenectomy.